Iniparib administered weekly or twice-weekly in combination with gemcitabine/carboplatin in patients with metastatic triple-negative breast cancer: a phase II randomized open-label study with pharmacokinetics
Sign Up to like & getrecommendations! Published in 2019 at "Breast Cancer Research and Treatment"
DOI: 10.1007/s10549-019-05305-w
Abstract: PurposeMetastatic triple-negative breast cancer (TNBC) is a phenotypic breast cancer subgroup with a very poor prognosis, despite standard treatments. Combined twice-weekly iniparib and gemcitabine/carboplatin (GC+tw-iniparib) showed benefit over gemcitabine/carboplatin in a randomized phase II trial,… read more here.
Keywords: gemcitabine carboplatin; twice weekly; iniparib; breast cancer ... See more keywords